Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Goodwill & Intangibles (2018 - 2025)

Akebia Therapeutics (AKBA) has disclosed Goodwill & Intangibles for 8 consecutive years, with $59.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Goodwill & Intangibles changed 0.07% to $59.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $59.0 million, a 0.07% change, with the full-year FY2025 number at $59.0 million, changed 0.07% from a year prior.
  • Goodwill & Intangibles was $59.0 million for Q4 2025 at Akebia Therapeutics, roughly flat from $59.0 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $163.2 million in Q4 2021 to a low of $9.0 million in Q3 2024.
  • A 5-year average of $77.8 million and a median of $59.0 million in 2022 define the central range for Goodwill & Intangibles.
  • Peak YoY movement for Goodwill & Intangibles: tumbled 80.0% in 2024, then skyrocketed 554.76% in 2025.
  • Akebia Therapeutics' Goodwill & Intangibles stood at $163.2 million in 2021, then decreased by 19.67% to $131.1 million in 2022, then dropped by 27.49% to $95.1 million in 2023, then crashed by 37.95% to $59.0 million in 2024, then grew by 0.07% to $59.0 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Goodwill & Intangibles are $59.0 million (Q4 2025), $59.0 million (Q3 2025), and $59.0 million (Q2 2025).